Composite medicinal product for treatment of pseudomonous gastroenteritis in young pigs

Abstract

Bacterial enteritis in growing pigs is a serious problem in modern pig farming affecting both the health of the herd and the economics of production, and the use of antimicrobials. The study was conducted at the end of the weaning and at the beginning of the growing period, i.e., in production groups where the cases of pseudomonas gastroenteritis in young pigs were observed in the past. These intestinal pathogens were widespread in both diarrheal and non-diarrheal samples. Pseudomonas aeruginosa was particularly common. Even in the absence of diarrhea, high prevalence and levels of excretion of this pathogen were detected making the presence of diarrhea an insufficient criterion for assessing the severity of the infection. There are numerous treatments for gastroenteritis in young pigs, but they have many drawbacks including daily administration with feed, a narrow spectrum of activity and various types of toxicity. Therefore, one way to reduce the negative consequences of antibacterial drug use is the development of composite agents. This method contributes to the implementation of the Russian Government Decree of September 25, 2017, on the strategy for preventing the development of drug-resistant populations of bacterial pathogens. Previously, the co-authors of this study, along with other authors, developed composite agents for the prophylaxis and treatment of gastroenteritis in young pigs of various infectious etiologies (Yersinia, Morganella, Salmonella, etc.), as reflected in the relevant sections of the Federal Institute of Industrial Property. This study examined the proportionality and feasibility of further study and, subsequently, the application of the developed proportions of the components of the new composite drug, its ability to prevent the development of drug-resistant populations and most strains of Pseudomonas aeruginosa, and, as a result, the therapeutic efficacy of the developed composite.